Abstract
The efforts to image hypoxia in oncology were stimulated by several questions about tumor biology and its role in response to treatment. What biochemical or physiological properties of tumors influence outcome of therapy? What drug or molecule is a natural substrate, precursor, or marker for the property of interest? Which characteristics of tumors are quantitatively, if not qualitatively different from normal tissues? Tumor hypoxia emerged as a feature that limits response to both radiation and chemotherapy and distinguishes tumors from nondiseased normal tissues, which are adequately oxygenated. It also appeared amenable to quantitation with PET imaging, provided one could develop an appropriate radiopharmaceutical that gave a positive image of oxygen-deprived tissue. A PET image of the metabolic rate of oxygen using [15O]O2 would produce a less desirable negative image for tissue with reduced oxygenation. Consideration of nonmalignant disease also identified two additional conditions where noninvasive quantification of oxygenation might be useful: myocardial infarct and cerebral ischemia.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Biskupiak, J. E., Grierson, J. R., Rasey, J. S., Martin, G. V., Krohn, K. A. Synthesis of an (Iodovinyl)misonidazole derivative for hypoxia imaging. J. Med. Chem. 34: 2165–2168, 1991.
Blasberg, R., Horowitz, M., Strong, J., Molnar, P., Patlak, C., Owens, E., Fenstermacher, J. Regional measurements of [14C]misonidazole distribution and blood flow in subcutaneous RT-9 experimental tumors. Cancer Res. 45: 1692–1699, 1985.
Brizel, D. M., Rosner, G. L., Harrelson, J., Prosnitz, L. R., Dewhirst, M. W. Pretreatment oxygenation profiles of human soft tissue sarcomas. Int. J. Radiat. Oncol. Biol. Phys. 30: 635–642, 1994.
Caldwell, J. H., Revenaugh, J. R., Martin, G. V., Johnson, P. S., Grierson, J. R., Rasey, J. S., Krohn, K. A. A Comparison of 2-[18F]-Fluoro-2-deoxy-glucose (FDG) and [3H] fluoromisonidazole (FMISO) Uptake During Low -Flow Ischemia. J. Nucl. Med. 36: 1633–8, 1995.
Casciari, J. J., Graham, M. M., Rasey, J. S. A modeling approach for quantifying tumor hypoxia with [F18]fluoromisonidazole PET time-activity data. Medical Physics 22: 1127–1139, 1995.
Casciari, J. J., Rasey, J. S. Determination of radiobiologically hypoxic fraction in multicellular spheroids from [H-3]fluoromisonidazole uptake data. Radiat. Res. 141: 28–36, 1995.
Chapman, J. D. Hypoxic sensitizers-implications for radiation therapy. N. Engl. J. Med. 301: 1429–1432, 1979.
Chapman, J. D. The detection and measurement of hypoxic cells in solid tumors. Cancer 54: 2441–2449, 1984.
Chapman, J. D., Franko, A. J., Sharplin, J. A marker for hypoxic cells in tumors with potential clinical applicability. Br. J. Cancer 43: 546–550, 1981.
Franko, A. J. Misonidazole and other hypoxia markers: metabolism and applications. Int. J. Radiat. Oncol. Biol. Phys. 12: 1195–1202, 1986.
Fyles, A., Milosevic, M., Kavanagh, M-C., Pintilie, M., Sun, A, Levin, W., Manchul, L., Keane, T.J., Hill, R. Hypoxia measured with a polarographic electrode correlates with radiation response in cervix cancer. Radiother. Oncol., submitted, 1996.
Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., Broder, G. J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14 (5): 831–838, 1988.
Grierson, J. R., Link, J. M., Mathis, C. A., Rasey, J. S., Krohn, K. A. A radiosynthesis of fluorine-18 fluoromisonidazole. J. Nucl. Med. 30: 343–350, 1989.
Grunbaum, Z., Freauff, S. J., Krohn, K. A., Wilbur, D. S., Magee, S., Rasey, J. S. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J. Nucl. Med. 28: 68–75, 1987.
Henk, J. M., Kunkler, P. B., Smith, C. W. Radiotherapy and hyperbaric oxygen in head and neck cancer. Final report of first controlled clinical trial. Lancet 2 (8029): 101–103, 1977.
Höckel, M., Knoop, C., Schlenger, K., Vorndran, B., Baußmann, E., Mitze, M., Knapstein, P. G., Vaupel, P. Intratumoral p02 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26: 45–50, 1993.
Höckel, M., Schlenger, K., Knoop, C., Vaupel, P. Oxygenation of carcinomas of the uterine cervix: evaluation by computered 02 tension measurements. Cancer Res. 51: 6098–6102, 1991.
Höckel, M., Vorndran, B., Schlenger, K., Baußmann, E., Knapstein, P. G. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecologic Oncol. 51: 141–149, 1993.
Jerabek, P. A., Patrick, T. B., Kilbourn, M. R., Dischino, D. D., Welch, M. J. Synthesis and biodistribution of 18F-labeled fluoronitroimidazoles: potential in vivo markers of hypoxic tissue. Int. J. Appl. Rad. Isotopes. 37: 599–605, 1986.
Knox, R. J., Knight, R. C., Edwards, J. Studies on the action of nitroimidazole drugs. The products of nitroimidazoles in a radiolytic model system. Int. J. Radiat. Oncol. Biol. Phys. 10: 1323–1326, 1983.
Koh, W-J., Bergman, K. S., Rasey, J. S., Peterson, L. M., Evans, M. L., Graham, M. M., Grierson, J. R., Lewellen, T. K., Krohn, K. A., Griffin, T. W. Evaluation of oxygenation status during fractionated radiotherapy in human non-small cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiat. Oncol. Biol. Phys., in press, 1996.
Koh, W-J., Rasey, J. S., Evans, M. L., Grierson, J. R., Lewellen, T. K., Graham, M. M., Krohn, K. A., Griffin, T. W. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 22: 1–13, 1992.
Lartigau, E., Le Ridant, A-M., Lambin, P., Weeger, P., Martin, L., Sigal, R., Lusinchi, A., Luboinski, B., Eschwege, F., Guichard, M. Oxygenation of head and neck tumors. Cancer 71: 2319–2325, 1993.
Martin, G. V., Biskupiak, J. E., Caldwell, J. H., Grierson, J. R., Krohn, K. A. Iodovinylmisonidazole: A metabolic marker for myocyte ischemia. J. Nucl. Med. 34: 918–924, 1993.
Martin, G.V., Caldwell, J. H., Graham, M. M, Grierson, J. R., Kroll, K, Cowan, M. J., Lewellen, T. K., Rasey, J. S., Casciari, J. J., Krohn, K. A. Noninvasive detection of hypoxic myocardium using 18Ffluoromisonidazole and positron emission tomography. J. Nucl. Med. 33: 2202–2208, 1992.
Martin, G. V., Cerqueira, M. D., Caldwell, J. H., Rasey, J. S., Embree, L., Krohn, K. A. Fluoromisonidazole: A metabolic marker of myocyte hypoxia. Circ. Res. 67: 240–244, 1990.
Martin, G. V., Rasey, J. S., Caldwell, J. C., Grunbaum, Z., Krohn, K. A. Fluoromisonidazole uptake in ischemic canine myocardium. J. Nucl. Med. 30: 194–201, 1989.
McClelland, R. A. Molecular interactions and biological effects of the products of reduction of nitroimidazoles. In: Adams, G.E., Breccia, A., Fiedlen, E.N., Wardman, P., eds. NATO Advanced Research Workshop on Selective Activation of Drugs by Redox Processes. New York, NY: Plenum Press, 125–136, 1990.
Moulder, J. E., Rockwell, S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 10: 695–712, 1984.
Moulder, J. E., Rockwell, S. Tumor hypoxia: its impact on cancer therapy. Cancer Metast. Rev. 5: 313341, 1987.
Overgaard, J., Sand-Hansen, H., Lindelov, B., Overgaard, M., Jorgensen, K., Rasmusson, B., Berthelsen, A. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5–85, Radiother. Oncol. 20: 143–149, 1991.
Raleigh, J. A., Koch, C. J. Importance of thiols in the reductive binding of 2-nitroimidazoles to macromolecules. Biochem. Pharm. 40: 2457–2464, 1990.
Rampling, R., Cruickshank, G., Lewis, A. D., Fitzsimmons, S. A., Workman, P. Direct measurement of pO2 distribution and bibreductive enzymes in human malignant brain tumors. Int. J. Radiat. Oncol. Biol. Phys. 29: 427–431, 1994.
Rasey, J. S., Evans, M. L. Detecting hypoxia in human tumors. In: Tumor Blood Supply and Metabolic Microenvironment: Characterizations and Implications for Therapy. P. Vaupel, R.K. Jain (Eds.). Funktionanalyse Biologischer Systeme 20, Gustav Fischer Verlag, 1991.
Rasey, J. S., Grunbaum, Z., Magee, S., Nelson, N. J., Olive, P. L., Durand, R. E., Krohn, K. A. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat. Res. 111: 292–304, 1987.
Rasey, J. S., Koh, W-J., Evans, M. L., Peterson, L. M., Lewellen, T. K., Graham, M. M., Krohn, K.A. Quantifying regional hypoxia in human tumors with positron emission tomography of [F18]fluoromisonidazole: A pretherapy study of 37 patients. Int. J. Rad. Oncol. Biol. Phys. 36: 417–428, 1996.
Rasey, J. S., Koh, W-J., Grierson, J. R., Grunbaum, Z., Krohn, K. A. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int. J. Rad. Oncol. Biol. Phys. 17 (5): 985–991, 1989.
Rasey, J. S., Nelson, N. J., Chin, L., Evans, M. L., Grunbaum, Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat. Res. 122: 301–308, 1990.
Revenaugh, J. R., Caldwell, J. H., Martin, G. V., Grierson, J. L., Krohn, K. A. Positron emission tomography (PET) imaging of myocardial hypoxia with 18F-fluoromisonidazole (FMISO) in post myocardial infarction patients. Circulation 84 (íI): 424, 1991. [abstract]
Spence, A. M., Graham, M. M., Muzi, M., Abbott, G. L., Krohn, K. A., Kapoor, R., Woods, S. D. Deoxyglucose lumped constant estimated in a transplanted rat astrocytic glioma by the hexose utilization index. J. Cereb. Blood Flow Metab. 10: 190–198, 1990.
Van Putten, L. M., Kaltman, R. F. Oxygenation status of a transplantable tumor during fractionated radiation therapy. J. Natl. Cancer Inst. 40: 441–451, 1968.
Vaupel, P., Schlenger, K., Knoop, C., Höckel, M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized 02 tension measurements. Cancer Res. 51: 3316–3322, 1991.
Whitmore, G.F., Varghese, A.J. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. Biochem. Pharm. 35: 97–103, 1986.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Rasey, J.S., Martin, G.V., Krohn, K.A. (1999). Quantifying Hypoxia with Radiolabeled Fluoromisonidazole: Pre-Clinical and Clinical Studies. In: Machulla, HJ. (eds) Imaging of Hypoxia. Developments in Nuclear Medicine, vol 33. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-1828-8_6
Download citation
DOI: https://doi.org/10.1007/978-94-017-1828-8_6
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-5157-8
Online ISBN: 978-94-017-1828-8
eBook Packages: Springer Book Archive